RESTRICTED STOCK UNIT AGREEMENT (Director Equity Incentive Program)Restricted Stock Unit Agreement • February 27th, 2013 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
On this __ day of _______________ (the “Grant Date”), Amgen Inc., a Delaware corporation (the “Company”), pursuant to its Amgen 2009 Director Equity Incentive Program (as amended from time to time, the “Program”) which implements the Amgen Inc. 2009 Equity Incentive Plan (the “Plan”), has granted to you, the grantee named above, _____________ restricted stock units (the “Units”) with respect to ______________ Shares on the terms and conditions set forth in this Restricted Stock Unit Agreement, including any appendix hereto (as further described in Section XIV below) containing special terms and conditions applicable to your country (collectively, this “Agreement”), and the Plan. Capitalized terms not defined herein shall have the meanings assigned to such terms in the Plan and/or the Program.
COLLABORATION AND LICENCE AGREEMENT Between AMGEN INC. and CELLTECH R&D LIMITED Re BEERLicence Agreement • February 27th, 2013 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Collaboration and Licence Agreement (the “Agreement”) is made and entered into the 10th day of May, 2002 (the “Effective Date”) by and between:
Amendment No. 2 to Expansion AgreementExpansion Agreement • February 27th, 2013 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This amendment to the Expansion Agreement (this “Amendment”) is made and entered into as of the 24th day of January, 2012 (the “Execution Date”), by and between Amgen Inc., a Delaware corporation with a place of business at 1 Amgen Center Drive, Thousand Oaks, CA 91320 (“Amgen”), and Glaxo Group Limited, registered in England as company number 305979, doing business as “GlaxoSmithKline” and having its principal office at Glaxo Wellcome House, Berkley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”).
AMENDMENT NO. 1 TO THE LICENSE AGREEMENTLicense Agreement • February 27th, 2013 • Amgen Inc • Biological products, (no disgnostic substances) • California
This Amendment No. 1 to the License Agreement (this “Amendment”), dated as of June 25, 2010 (the “Amendment Effective Date”), is made by and between Amgen Inc., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and Takeda Pharmaceutical company Limited, a Japanese corporation having an address of 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645 (“Licensee”).
AMENDMENT NO. 2 TO THE LICENSE AGREEMENTLicense Agreement • February 27th, 2013 • Amgen Inc • Biological products, (no disgnostic substances) • California
This Amendment No. 2 to the License Agreement (this “Amendment”), dated as of June 29, 2012 (the “Amendment Effective Date”), is made by and between Amgen Inc., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and Takeda Pharmaceutical company Limited, a Japanese corporation having an address of 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645 (“Licensee”).
Amendment No. 1 to Collaboration AgreementCollaboration Agreement • February 27th, 2013 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This amendment to the Collaboration Agreement (this “Amendment”) is made and entered into as of the 24th day of January, 2012 (the “Execution Date”), by and between Amgen Inc., a Delaware corporation with a place of business at 1 Amgen Center Drive, Thousand Oaks, CA 91320 (“Amgen”), and Glaxo Group Limited, registered in England as company number 305979, doing business as “GlaxoSmithKline” and having its principal office at Glaxo Wellcome House, Berkley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”).
Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. AMENDMENT NO. 1 TO SOURCING AND SUPPLY AGREEMENT BETWEEN...Sourcing and Supply Agreement • February 27th, 2013 • Amgen Inc • Biological products, (no disgnostic substances)
This Amendment No. 1 (“Amendment No. 1”) to Sourcing and Supply Agreement (the “Agreement”) is being made by and between Amgen USA Inc. (“Amgen”) and DaVita Healthcare Partners Inc. f/k/a DaVita Inc. (“Dialysis Center”) and effective as of January 1, 2013 (the “Amendment No. 1 Effective Date”).
